ES2098948T3 - Procedimientos de ensayo de analogos de acido nucleico. - Google Patents

Procedimientos de ensayo de analogos de acido nucleico.

Info

Publication number
ES2098948T3
ES2098948T3 ES94916331T ES94916331T ES2098948T3 ES 2098948 T3 ES2098948 T3 ES 2098948T3 ES 94916331 T ES94916331 T ES 94916331T ES 94916331 T ES94916331 T ES 94916331T ES 2098948 T3 ES2098948 T3 ES 2098948T3
Authority
ES
Spain
Prior art keywords
nucleic acid
acid analog
amount
test procedures
analog test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916331T
Other languages
English (en)
Inventor
Christopher John Stanley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PNA Diagnostics ApS Denmark
Original Assignee
PNA Diagnostics ApS Denmark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PNA Diagnostics ApS Denmark filed Critical PNA Diagnostics ApS Denmark
Application granted granted Critical
Publication of ES2098948T3 publication Critical patent/ES2098948T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

UN PROCEDIMIENTO DE ENSAYO PARA CUANTIFICAR LA CANTIDAD DE UNA MUESTRA INICIADORA EN UN PROCEDIMIENTO DE AMPLIFICACION DE ACIDO NUCLEICO TAL COMO PCR QUE INVOLUCRA INTENTAR LA AMPLIFICACION EN LA PRESENCIA DE VARIAS CANTIDADES DE UN ANALOGO DE UN ACIDO NUCLEICO EN SUFICIENTE CANTIDAD PARA INHIBIR DICHO PROCEDIMIENTO DE AMPLIFICACION MEDIANTE LA INTERACCION SELECTIVA CON ESPECIES DE ACIDO NUCLEICO PRESENTES, POR EJEMPLO UN PNA COMO DESCRITO EN WO-02-20703. LA CANTIDAD DE LA MUESTRA ES DADA POR LA CANTIDAD DEL ANALOGO DE ACIDO NUCLEICO QUE ES CRITICO PARA CAUSAR EL FALLO DE DICHO PROCEDIMIENTO DE AMPLIFICACION.
ES94916331T 1993-06-02 1994-05-31 Procedimientos de ensayo de analogos de acido nucleico. Expired - Lifetime ES2098948T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939311386A GB9311386D0 (en) 1993-06-02 1993-06-02 Nucleic acid analogue assay procedures

Publications (1)

Publication Number Publication Date
ES2098948T3 true ES2098948T3 (es) 1997-05-01

Family

ID=10736511

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916331T Expired - Lifetime ES2098948T3 (es) 1993-06-02 1994-05-31 Procedimientos de ensayo de analogos de acido nucleico.

Country Status (9)

Country Link
US (1) US5912145A (es)
EP (1) EP0701627B1 (es)
JP (1) JP2842694B2 (es)
AU (1) AU6802994A (es)
DE (1) DE69401661T2 (es)
DK (1) DK0701627T3 (es)
ES (1) ES2098948T3 (es)
GB (1) GB9311386D0 (es)
WO (1) WO1994028171A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629178A (en) * 1994-10-28 1997-05-13 Genetics & Ivf Institute Method for enhancing amplification in the polymerase chain reaction employing peptide nucleic acid (PNA)
JP4040087B2 (ja) * 1995-05-05 2008-01-30 アプレラ コーポレイション Ｐｃｒ増幅とハイブリダイゼーションプロービングアッセイとを組み合わせた方法およびそのための試薬
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US5939262A (en) 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6617422B1 (en) 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
ATE490777T1 (de) 1999-06-01 2010-12-15 Baylor College Medicine Zusammensetzungen und verfahren zur therapeutischen anwendung einer mit dem gen atonal assoziierten sequenz
AU2001229576A1 (en) * 2000-01-15 2001-07-24 Genelabs Technologies, Inc. Nucleic acid binding site assay and selection method
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
ATE443133T1 (de) 2002-02-01 2009-10-15 Life Technologies Corp Oligonukleotidzusammensetzungen mit verbesserter effizienz
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20030211483A1 (en) * 2002-05-09 2003-11-13 Schroeder Benjamin G. Methods for the enrichment of low-abundance polynucleotides
KR101170653B1 (ko) 2002-08-12 2012-08-03 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
ATE469245T1 (de) 2004-09-14 2010-06-15 Univ Colorado Auf genetischem targeting basierendes verfahren zur behandlung mit bucindolol
EP1861721B1 (en) 2005-03-10 2017-05-03 Gen-Probe Incorporated Systems and methods to perform assays for detecting or quantifying analytes within samples
EP1933857A2 (en) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
AU2007249812B2 (en) 2006-05-12 2013-08-15 Cepheid DNA recombination junction detection
CN105769931B (zh) 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
US20100129902A1 (en) 2008-11-24 2010-05-27 Erhard Ralf Schoenbrunner Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR)
JP5785942B2 (ja) 2009-06-29 2015-09-30 ルミネックス コーポレーション ヘアピンコンフォメーションを有するキメラプライマーおよびその使用法
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
WO2011032088A1 (en) 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
ES2671570T3 (es) 2009-09-14 2018-06-07 Sillajen Biotherapeutics, Inc. Terapia combinada contra el cáncer con virus oncolítico de vaccinia
MX337062B (es) 2009-12-10 2016-02-11 Ottawa Hospital Res Inst Rabdovirus oncolítico.
DK2515899T3 (en) 2009-12-23 2016-08-15 Arca Biopharma Inc METHODS AND COMPOSITIONS FOR CARDIOVASCULAR DISEASES AND CONDITIONS
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
CA2828532A1 (en) 2011-02-28 2012-11-22 University Of Iowa Research Foundation Anti-mullerian hormone changes in pregnancy and prediction of adverse pregnancy outcomes and gender
EP2683835B1 (en) 2011-03-08 2017-01-11 King Abdullah University Of Science And Technology Molecular biomarker set for early detection of ovarian cancer
US9364532B2 (en) 2011-06-08 2016-06-14 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
US10040853B2 (en) 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
AU2014221143B2 (en) 2013-02-21 2019-02-07 Turnstone Limited Partnership Vaccine composition
WO2015051110A1 (en) 2013-10-03 2015-04-09 Oklahoma Medical Research Foundation Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
EA031654B1 (ru) 2014-01-10 2019-02-28 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Гидроксиформамидные производные и их применение
GB201411567D0 (en) * 2014-06-30 2014-08-13 Epistem Ltd Quantification methods
EP3224362A4 (en) 2014-11-26 2018-06-06 The Regents of The University of California Therapeutic compositions comprising transcription factors and methods of making and using the same
US20190390278A1 (en) 2017-01-26 2019-12-26 Oklahoma Medical Research Foundation Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
CA3116539C (en) 2018-10-18 2023-10-03 Oklahoma Medical Research Foundation Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity
AU2019371161A1 (en) 2018-10-31 2021-06-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Biomarkers and methods of use for radiation-induced lung injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219727A (en) * 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
GB9016163D0 (en) * 1990-07-24 1990-09-05 Cemu Bioteknik Chemical method
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
GB9211979D0 (en) * 1992-06-05 1992-07-15 Buchard Ole Uses of nucleic acid analogues

Also Published As

Publication number Publication date
GB9311386D0 (en) 1993-07-21
AU6802994A (en) 1994-12-20
WO1994028171A1 (en) 1994-12-08
US5912145A (en) 1999-06-15
JP2842694B2 (ja) 1999-01-06
DE69401661T2 (de) 1997-06-12
DE69401661D1 (de) 1997-03-13
EP0701627B1 (en) 1997-01-29
EP0701627A1 (en) 1996-03-20
DK0701627T3 (da) 1997-07-21
JPH08510384A (ja) 1996-11-05

Similar Documents

Publication Publication Date Title
ES2098948T3 (es) Procedimientos de ensayo de analogos de acido nucleico.
ES2040199T1 (es) Procedimiento para controlar la contaminacion de reacciones de amplificacion de acido nucleico.
GT197746150A (es) Nuevos agentes antielminticos y proceso para su prepracion
MX9300766A (es) Piridonas sustituidas por sulfonilbencilo, procedimiento para su obtencion y medicamentos que las contienen.
ES2052610T3 (es) Un metodo de determinacion de anfetamina y/o metanfetamina en una muestra de ensayo.
AR059433A1 (es) Identificacion y uso de genes blanco para el control de nematodos parasitos de plantas
AR246663A1 (es) Composicion miticida y metodo para controlar concentraciones de aranuelas.
ES2058299T3 (es) Metodo de extraer atp.
ES2113105T3 (es) Reactivos para uso en bioluminiscencia.
AR037771A1 (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal
BR0108212A (pt) Agente e processo para tingimento de fibras de queratina
ATE234637T1 (de) Verbesserungen von oder in bezug auf endometrialfunktion
ES455714A1 (es) Procedimiento de fabricacion de soportes para filtros biolo-gicos.
MX2021008867A (es) Composiciones reactantes marcadas de intensidad alta y metodos de secuenciamiento.
ES2096973T3 (es) Fosfazenos que contienen radicales organicos de silicio, proceso para su preparacion, y su empleo.
ES2180126T3 (es) Procedimiento y recinto para la regeneracion de un catalizador que incluye un control del final de la combustion.
ES2059311T3 (es) Extraccion de sustancias de ensayo.
ES2062256T3 (es) Procedimiento para producir amida de acido alfa-hidroxiisobutirico.
ES2083840T3 (es) Suspensiones acuosas estables de zeolitas, su procedimiento de obtencion y su utilizacion.
ES2032202T3 (es) Fabricacion de liquidos organicos.
AR065847A1 (es) Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso.
ES2173178T3 (es) Composicion catalitica mcm-22 mejorada.
AR014528A1 (es) Adn que comprende una secuencia de nucleotidos que se puede traducir a una proteina con actividad de invertasa, proteina derivada del adn que tieneactividad de invertasa pero que carece de actividad beta-fructofuranosidasa; metodo para producir adn y dicho metodo donde el adn es producido por una
AR016696A1 (es) Metodo de ensayo y planta producida mediante el mismo
ES2058211T3 (es) Procedimiento para la auto-ejecucion de la cinetica de enzimas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701627

Country of ref document: ES